Company Description
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system.
It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
The company also develops mavorixafor that is in Phase 3 4WARD clinical trial to evaluate the efficacy, safety, and tolerability of oral, once-daily mavorixafor with or without stable doses of G-CSF in people with congenital, acquired primary autoimmune, or idiopathic CN who are experiencing recurrent and/or serious infections.
It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications; and with Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand.
The company is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 143 |
| CEO | Paula Ragan |
Contact Details
Address: 61 North Beacon Street, 4th Floor Boston, Massachusetts 02134 United States | |
| Phone | 857 529 8300 |
| Website | x4pharma.com |
Stock Details
| Ticker Symbol | XFOR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001501697 |
| CUSIP Number | 98420X202 |
| ISIN Number | US98420X1037 |
| Employer ID | 27-3181608 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Mark Baldry M.B.A. | Chief Commercial Officer |
| Dr. Adam R. Craig M.B.A., M.D., Ph.D. | Executive Chair |
| John P. Volpone | President |
| Dr. Richard Peters M.D., Ph.D. | Founder |
| Dr. Renato T. Skerlj Ph.D. | Founder |
| Dr. Keith T. Flaherty M.D. | Founder and Member of Corporate Advisory Board |
| David H. Kirske | Chief Financial Officer |
| Dr. Mary DiBiase Ph.D. | Chief Operating Officer |
| Natasha Thoren Esq. | Chief Legal and Compliance Officer |
| Dr. Christophe Arbet-Engels M.B.A., M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 10, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Sep 10, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 25, 2025 | D | Notice of Exempt Offering of Securities |
| Aug 25, 2025 | 8-K | Current Report |
| Aug 20, 2025 | SCHEDULE 13G | Filing |
| Aug 19, 2025 | SCHEDULE 13G | Filing |
| Aug 18, 2025 | SCHEDULE 13G | Filing |
| Aug 18, 2025 | SCHEDULE 13D | Filing |
| Aug 15, 2025 | SCHEDULE 13D/A | Filing |
| Aug 14, 2025 | SCHEDULE 13G/A | Filing |